Physician profile
Michael John Kaster
NPI 1891180980
$12,593.63
in general payments reported to CMS, 2019-2025
18 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $195 · 2021: $413 · 2022: $3,263 · 2023: $6,047 · 2024: $858 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,575 · Travel and Lodging: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,574.66 |
| Travel and Lodging | $1,881.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $4,424.62 | 2023 | Photofrin |
| Ethicon INC. | $3,016.51 | 2021-2025 | Monarch Platform |
| Pulmonx Corporation | $2,494.00 | 2021-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Noah Medical Corporation | $662.11 | 2023-2025 | Galaxy |
| Galvanize Therapeutics, INC | $540.24 | 2023-2025 | Aliya System |
| Astrazeneca Pharmaceuticals LP | $246.58 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Edwards Lifesciences Corporation | $230.93 | 2023 | |
| Glaxosmithkline, LLC. | $213.23 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Inari Medical, INC. | $197.23 | 2020-2021 | |
| Medtronic, INC. | $161.15 | 2023 | Illumisite |
| Takeda Pharmaceuticals U.S.A., INC. | $146.19 | 2020-2024 | Glassia |
| Genzyme Corporation | $71.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $66.00 | 2024-2025 | Keytruda |
| Abiomed | $42.04 | 2024 | Impella |
| Amgen INC. | $24.29 | 2025 | Tavneos |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.71 | 2024 | Ofev |
| La Jolla Pharmaceutical Company | $19.19 | 2025 | Giapreza |
| Regeneron Healthcare Solutions, INC. | $14.68 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.